Design and evaluation of novel liposome-based peptide vaccines for improved efficacy against group A streptococcal infections of the mucosa and skin

Loading...
Thumbnail Image
File version
Primary Supervisor

Good, Michael

Pandey, Manisha

Other Supervisors

Batzloff, Michael

Editor(s)
Date
2018
Size
File type(s)
Location
License
Abstract

Streptococcus pyogenes (group A streptococcus, GAS) is an important human pathogen that is responsible for a range of diseases. Non-invasive diseases include pharyngitis, scarlet fever and pyoderma/impetigo. GAS is also capable of causing invasive diseases such as streptococcal toxic shock syndrome and necrotizing fasciitis. There is a high chance of mortality associated with GAS invasive diseases, with approximately 8-23% of patients dying within 7 days of infection. Consecutive GAS infections may give rise to auto-immune complications, including acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Approximately 2-3% of patients who acquire streptococcal pharyngitis develop ARF. Skin-associated GAS strains have also been linked to cases of ARF. A vaccine that can stop the progression of disease from the primary sites of infection (URT and skin) is desperately needed.

Journal Title
Conference Title
Book Title
Edition
Volume
Issue
Thesis Type

Thesis (PhD Doctorate)

Degree Program

Doctor of Philosophy (PhD)

School

Institute for Glycomics

Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement

The author owns the copyright in this thesis, unless stated otherwise.

Item Access Status
Note
Access the data
Related item(s)
Subject

Medical and Health Sciences

Peptide vaccines

Streptococcal infections

Liposomal-based delivery systems

Mucosal vaccine platform

Skin-infection

Persistent link to this record
Citation